Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 19;12(12):1904.
doi: 10.3390/biom12121904.

Oxidative Stress and Phototherapy in Atopic Dermatitis: Mechanisms, Role, and Future Perspectives

Francesco Borgia  1 , Federica Li Pomi  1 , Mario Vaccaro  1 , Clara Alessandrello  2 , Vincenzo Papa  2 , Sebastiano Gangemi  2
Affiliations
Review

Oxidative Stress and Phototherapy in Atopic Dermatitis: Mechanisms, Role, and Future Perspectives

Francesco Borgia et al. Biomolecules. .

Abstract

Atopic dermatitis is a chronic inflammatory skin disease in which the overproduction of reactive oxygen species plays a pivotal role in the pathogenesis and persistence of inflammatory lesions. Phototherapy represents one of the most used therapeutic options, with benefits in the clinical picture. Studies have demonstrated the immunomodulatory effect of phototherapy and its role in reducing molecule hallmarks of oxidative stress. In this review, we report the data present in literature dealing with the main signaling molecular pathways involved in oxidative stress after phototherapy to target atopic dermatitis-affected cells. Since oxidative stress plays a pivotal role in the pathogenesis of atopic dermatitis and its flare-up, new research lines could be opened to study new drugs that act on this mechanism, perhaps in concert with phototherapy.

Keywords: NRF2; PON1; UVA; UVB; atopic dermatitis; oxidative stress; phototherapy; reactive oxygen species; skin disease; ultraviolet.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Oxidative stress causes direct damage to the cell membrane and DNA which leads to skin barrier defect. Furthermore, the activation of the NF-κB pathway leads to the release of IL-6, IL-8, IL-9, and IL-33. The defect of the skin barrier causes inflammation of the dermis and release of histamine and itching, leading in turn to an increased release of IL-6, IL-8, IL-9, and IL-33. All these mechanisms determine a further increase in the release of ROS, establishing a vicious circle that is self-maintaining. Created with BioRender.com.
Figure 2
Figure 2
UVR modulation on the expression of cytoprotective genes. The figure shows the diametrically opposite effects of UVA and UVB. UVA-mediated oxidation acts on two different levels by promoting the intracytoplasmic accumulation of free NRF2 which, once oxidized, translocates to the nucleus where, dimerizing with AP-1, it acts as a transcriptional activator of cytoprotective genes. Further upregulation of HMOX-1 is provided by the oxidation of HIF-1. UVB-mediated oxidation indirectly inactivates the transcription of cytoprotective genes through direct DNA damage. The lack of this cytoprotective action in turn results in NLRP3 inflammasome activation and consequent pyroptosis.
See this image and copyright information in PMC

References

    1. Campanati A., Bianchelli T., Gesuita R., Foti C., Malara G., Micali G., Amerio P., Rongioletti F., Corazza M., Patrizi A., et al. Comorbidities and treatment patterns in adult patients with atopic dermatitis: Results from a nationwide multicenter study. Arch. Dermatol. Res. 2021;314:593–603. doi: 10.1007/s00403-021-02243-w. - DOI - PMC - PubMed
    1. Xiao H., Gu X., Huang Y., Zhu W., Shen M. Phototherapy for atopic dermatitis: Systematic review and network meta-analysis of randomized controlled trials. Photodermatol. Photoimmunol. Photomed. 2022;38:233–240. doi: 10.1111/phpp.12741. - DOI - PubMed
    1. Mastorino L., Rosset F., Gelato F., Ortoncelli M., Cavaliere G., Quaglino P., Ribero S. Chronic pruritus in atopic patients treated with dupilumab: Real life response and related parameters in 354 patients. Pharmaceuticals. 2022;15:883. doi: 10.3390/ph15070883. - DOI - PMC - PubMed
    1. Miniotti M., Lazzarin G., Ortoncelli M., Mastorino L., Ribero S., Leombruni P. Impact on health-related quality of life and symptoms of anxiety and depression after 32 weeks of dupilumab treatment for moderate-to-severe atopic dermatitis. Dermatol. Ther. 2022;35 doi: 10.1111/dth.15407. - DOI - PMC - PubMed
    1. Tintle S., Shemer A., Suárez-Fariñas M., Fujita H., Gilleaudeau P., Sullivan-Whalen M., Johnson-Huang L., Chiricozzi A., Cardinale I., Duan S., et al. Reversal of atopic dermatitis with narrow-band uvb phototherapy and biomarkers for therapeutic response. J. Allergy Clin. Immunol. 2011;128:583–593. doi: 10.1016/j.jaci.2011.05.042. - DOI - PMC - PubMed

LinkOut - more resources